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ABSTRACT 
The studies included in this thesis examined the population-level effect of human 
Papillomavirus (HPV) vaccination on incidence of HPV-related disease outcomes, and 
participation to cervical screening following vaccination. 
In study I, a cohort of young Swedish girls ages 10 to 24 was followed for HPV vaccination 
and condyloma to investigate the effect of vaccination on condyloma by vaccine dose. The 
results showed greatest protection against condyloma following administration of three HPV 
vaccine doses. Considerable protection against condyloma was also seen after vaccination 
with two doses of the quadrivalent HPV (qHPV) vaccine. Risk reductions of 71% and 82% 
following vaccination with two and three doses, respectively, were seen when vaccination 
was initiated prior age 17. Greater protection against condyloma was seen in those younger at 
vaccination initiation. 
In study II, a birth cohort of women at cervical screening ages (born between 1977 and 1987) 
was followed for HPV vaccination, invitation to cervical screening, and attendance to 
screening. The results showed that, compared to unvaccinated women, women HPV 
vaccinated through opportunistic vaccination were equally likely, if not more likely to attend 
organized cervical screening following an invitation letter to cervical screening. 
In study III, a cohort of young Swedish girls and women at ages 23 to 29 was followed for 
HPV vaccination and cervical lesions, i.e. cervical intraepithelial neoplasia (CIN) stage 2 or 
worse (CIN2+) and CIN stage 3 or worse (CIN3+), to investigate the effect of vaccination on 
incidence of cervical lesions after three-dose vaccination. The results showed reductions in 
risk for CIN2+ and CIN3+ following vaccination in girls and young women that initiated 
vaccination up until age 29. Greater reductions in risk for cervical lesions were seen in those 
younger at vaccination initiation. A maximum reduction of 75% and 84% in risk for CIN2+ 
and CIN3+, respectively, were seen when vaccination was initiated prior to age 17. 
In study IV, we assessed the incidence of condyloma following the introduction of qHPV in 
Sweden. During the study period, girls were mainly vaccinated via opportunistic HPV 
vaccination, and vaccination coverage remained rather low. Declines in condyloma incidence 
in girls below age 20 were seen following the introduction of qHPV vaccination in Sweden 
and confirm anticipated effects. In addition, we observed declines in incidence of condyloma 
among men and in women age 20 and above indicates possible herd protection.  
In conclusion, the results of these studies contribute to the existing evidence on the 
population level effect of HPV vaccination and the disease monitoring of HPV related 
disease in an era where opportunistic HPV vaccination was available. The results of study I 
have also contributed to the discussions on reduced vaccine dosing schedules. Future 
monitoring of the disease burden over time, as well as observational studies comparing 
vaccinated and unvaccinated individuals, are necessary to evaluate whether the organized 
school-based vaccination program has the anticipated effect in the population.  
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1 BACKGROUND 
The human Papillomavirus (HPV) is found in the large majority of cervical cancer cases and 
is believed to be a necessary but not sufficient cause of cervical cancer (1–4). HPV DNA was 
first identified in cervical cancer cases in the early 1980s (3). Not long after this discovery, it 
was shown that the vast majority of all cervical cancers contain HPV (4,5). Currently, there 
are over 200 different types of HPV identified (6,7), but not all HPV have the potential to 
cause malignancies. About 40 types of HPV infect the genital tract and the oncogenic 
potential of thirteen of these HPV-types (high-risk HPV) has been acknowledged by the 
International Agency for Research on Cancer (IARC) (8). Genital HPV is transmitted via 
skin-to-skin contacts, mainly during sexual intercourse. Infection with HPV is common; 
around 291 million women worldwide are HPV infected (9). The overall prevalence of HPV 
in women with normal cytology is about 10% and is highest among young sexually active 
women (9). Though there are differences by regions, there is generally a second peak in HPV 
prevalence at older ages (9,10). The overall life-time probability for both men and women to 
acquire an HPV infection before age 45 is estimated to be over 80% (11). 
1.1 PROPHYLACTIC HPV VACCINES 
The recognition that infection with HPV can lead to cervical cancer has expedited the 
development of vaccines preventing infection. The HPV vaccines currently available are 
subunit L1 virus-like particles (VLPs) vaccines and include an adjuvant which is a solution 
that enhances the immune response. L1 is a capsid protein that can self-assemble to VLPs 
which trigger an antibody response in the body. In contrast to live-attenuated or weakened 
virus vaccines there is no risk that vaccination can cause the disease as subunit vaccines do 
not include infectious viral DNA (12). This is comforting considering the oncogenic potential 
of HPV. 
Three prophylactic HPV vaccines have received marketing authorization by both the Food 
and Drug Administration (FDA) and European Medicines Agency (EMA). In 2006, the first 
prophylactic HPV vaccine, the quadrivalent HPV (qHPV) vaccine (Gardasil
TM
; Merck), was 
approved targeting HPV types 6, 11, 16, and 18 (13,14). The high-risk HPV types 16 and 18 
are found in 70% of cervical cancer cases (2,15). The 9-valent HPV (9vHPV) vaccine 
(Gardasil 9
TM
; Merck) was approved in 2014 by the EMA and in 2015 by the FDA offering 
protection against five additional high-risk HPV types (HPV types 31, 33, 45, 52, 58) that are 
estimated to cause about 20% of cervical cancers (16,17). The bivalent HPV (bHPV) vaccine 
(Cervarix
TM
; GlaxoSmithKline) including HPV types 16 and 18 was licensed in 2007 by the 
EMA and in 2009 by the FDA (18,19). As of January 2016, 66 countries have introduced 
HPV vaccination in their national immunization program (20). 
The qHPV and 9vHPV vaccines are indicated for use in girls and women to protect against 
HPV vaccine type related condyloma, and cancer and precursor lesions of the cervix, vulva, 
and anus. qHPV and 9vHPV vaccination is also approved in boys and men for prevention of 
condyloma, anal cancer, and its precursor lesions related to HPV types included in the 
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vaccine (21,22). The bHPV vaccine is indicated for girls and women for prevention of HPV 
type 16 and 18 related cervical cancer and precursor lesions of cervical cancer (23). 
1.1.1 Results from clinical trials 
The HPV vaccines have been extensively tested in Phase III trials before market authorization 
was granted. The vaccines elicit good immune responses. Shortly after vaccination, there is a 
peak in serum antibody concentration of vaccine HPV-types after which serum antibody 
concentrations subside until reaching a plateau level (24,25). The antibody responses seen 
after HPV vaccination were higher than the antibody responses observed after natural HPV 
infections (25–28). Furthermore, nearly all women that were vaccinated seroconverted 
(26,29). In contrast, the rate of seroconversion after a natural HPV infection is about 60% 
following an incident infection with HPV type 16 (30). For qHPV vaccination, about 40% of 
the women were no longer HPV type 18 seropositive 4 years post-vaccination (31). However, 
there are no signs of lower efficacy against HPV related disease so far (29,31). 
Persistent HPV infections, condyloma, and premalignant disease are the first endpoints that 
can be studied in the clinical trial data as their incubation times are considerably shorter than 
the incubation time of cervical cancer. With efficacy rates of up to 100%, vaccine efficacy 
against HPV vaccine type-related anogenital and cervical disease was high in populations that 
were both seronegative and DNA negative for HPV vaccine types at vaccination initiation 
(29,32–36). The vaccine is less effective in intention to treat populations, i.e. a population 
composed of a mixture of women with past or current HPV exposure or HPV naïve women, 
most reflective for the real-life population (24,29,32–34,36). 
The bHPV and qHPV vaccines do not have an effect on ongoing HPV infections. It was 
shown that the bHPV vaccine does not influence HPV clearance and no therapeutic effect 
was observed (37). There is no evidence that the qHPV vaccine has an effect on disease 
progression to high-grade cervical lesions in women that are HPV infected at the time of 
vaccination (38). Nevertheless, women previously infected with one or more HPV vaccine 
types may still benefit from HPV vaccination as the vaccine offers protections against the 
remaining HPV vaccine types to which the individual has not currently been exposed (39). 
Results on efficacy of the 9vHPV vaccine in clinical trial settings have recently been 
published. As the effect of HPV vaccination has been shown previously, it is considered 
unethical for individuals assigned to the non-intervention group to receive a placebo, instead 
individuals received the qHPV vaccine (40). Incidence of persistent HPV infections and high 
grade cervical, vaginal, and vulvar disease due to infection with HPV types 6, 11, 16, and 18 
should therefore be comparable after vaccination with qHPV and 9vHPV vaccine. This was 
confirmed in the trial data (40). Furthermore, the vaccine efficacy against persistent HPV 
infection and high grade cervical, vaginal, and vulvar disease for the five HPV vaccine types 
not included in the qHPV vaccine approached 100% in a population seronegative and DNA 
negative for vaccine HPV types at vaccination initiation (40). 
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1.1.2 Cross-protective properties of HPV vaccines 
The clinical trial data for both bHPV and qHPV vaccine has shown cross-protective 
properties against non-vaccine type related HPV infection and cervical lesions (24,41–43). At 
the population level, lower prevalence of non-vaccine HPV types such as 31, 33, and 45 were 
found advocating cross protection (44,45). Moderate protection against persistent infection 
with non-high risk HPV types 6, 11, and 74 has been reported after vaccination with the 
bHPV vaccine (46). After England included the bHPV in the national immunization program 
a decrease in incidence of condyloma, the result of an infection with non-high risk HPV types 
6 or 11, was observed (47). 
1.1.3 Vaccination schedules 
The HPV vaccines were initially licensed as three-dose vaccination schedules with the qHPV 
and 9vHPV vaccines given at 0, 2, and 6 months, and the bHPV vaccine given at 0, 1, and 6 
months. Immunogenicity results have indicated non-inferiority in antibody response for HPV 
vaccine types when comparing three versus two dose antibody responses given 6 months 
apart (48–51). Studies conducted using infection as endpoint have also shown protection 
against infection with HPV 16 and/or 18 after vaccination with one and two doses of the 
bHPV vaccine (51–53). A review of the existing data on vaccination with two doses has led 
to a recommendation of a two-dose schedule by the World Health Organization (WHO). A 
two-dose schedule, given 6 months apart, may be given to girls at ages 9 to 13 (54). 
1.2 VACCINE EFFICACY AND EFFECTIVENESS 
Vaccine efficacy cannot be interpreted as vaccine effectiveness which is an estimate of the 
vaccine’s performance when introduced in the target population (55). Vaccine efficacy is 
measured in a clinical trial setting where optimal conditions regarding to the selection of the 
study population, controlled and randomized distribution of the vaccine, measurement of the 
outcome, and vaccination adherence apply. Vaccine efficacy approximates the true effect of 
the vaccine which can be expected under ideal conditions. Such conditions are not at hand in 
routine practice. The clinical trials on HPV vaccination included different study populations 
varying from an ideal study population that approximates a sexually naïve, and thus HPV 
negative, population to an intention-to-treat population that represents an approximation of a 
real-life more heterogeneous population of HPV naïve women and women with current and 
previous HPV exposure. However, women included in the intention-to-treat populations of 
clinical trials also need to fulfil certain inclusion and exclusion criteria such as: maximum 
number of previous sexual partners, no prior abnormal pap-smear, and no history of 
condyloma or a colposcopy (26,36). This makes the study population in clinical trials 
different from the general population. Vaccine effectiveness is preferable from a public health 
perspective as it provides information on HPV vaccination programs, strategies, vaccine 
access, distribution, and direct and indirect effects of vaccination. Randomized clinical trials 
can effectively control for known and unknown biases, however, in vaccine effectiveness 
observational studies there is no inherent control for bias and they are therefore susceptible to 
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confounding (55). Therefore, vaccine effectiveness results at the population level should be 
interpreted with caution. 
1.3 HPV-RELATED DISEASE OUTCOMES 
Though HPV has been mainly associated with cervical cancer, its role in the development of 
precursors and cancers of the vulva, vagina, anus, penis, and oropharynx has been recognized 
(8). In addition non-high risk HPV types 6 and 11 have been found in the majority of the 
condyloma cases (56–58). The HPV-related disease outcomes condyloma, precancerous 
lesions and cancer of the cervix will be discussed in more detail below. 
1.3.1 Condyloma 
The non-HR HPV types 6 and 11 are found in about 90% of condyloma cases (57). The risk 
to develop condyloma following an infection with HPV types 6 or 11 is considerable. A 
previous study estimated that 66% of women with a HPV type 6 or 11 infection develop 
condyloma within 3 years (58). The infectivity rate, the percentage of individuals that 
develop condyloma after sexual intercourse with a partner with condyloma, is estimated to be 
64% (59). Individuals with condyloma can receive pharmaceutical treatment with 
podophyllotoxin or imiquimod which can be applied at home. These treatments are 
considered to be the first-line therapy for the first occurrence of condyloma (60). Other 
treatments include cryotherapy, application of trichloracetic acid, and surgical treatment 
(60,61). Condyloma is a benign disease, but the patient can experience considerable anxiety 
or depression and discomfort (62). Recurrent disease is common and risk for recurrence 
varies by mode of treatment (61). It is estimated that about 20-30% of the cases recur (60). 
The median time between infection with HPV and condyloma is typically 1-6 months, 
although longer periods have also been reported (57–59). Condyloma is common in both men 
and women; the incidence of condyloma starts to rise sharply from age ~15 to peak in the 
early to mid-20s for both men and women (63–65). The peak incidence of condyloma is close 
to 1% (63–65). It is furthermore estimated that 1 out of 10 women will be diagnosed with 
condyloma before the age of 45 (66). 
1.3.2 Cervical abnormalities and cancer of the cervix 
The development of cervical cancer after an infection with HPV can take more than a decade 
(8). Cervical cancer is categorized by its histology and squamous cell cancer and 
adenocarcinoma of the cervix are the most common types of cervical cancer. Most women 
that are HPV infected clear the infection within 2 years (67,68). Women that remain 
persistently HPV infected are at higher risk for developing cervical lesions (69,70) that may 
develop into invasive cervical cancer (71). The risk for developing a cervical abnormality 
varies by HPV type and is generally higher for oncogenic HPV types (69,70,72). 
The high-risk HPV types 16 and 18 are found in 70% of cervical cancer cases (2,15). These 
types are also detected in about half of the precursor lesions of cervical cancer and the 
proportion attributed to types 16 and 18 increases with lesion severity (73). An additional 
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20% of the cervical cancer cases are positive for HPV types 31, 33, 45, 52, and 58, the types 
included in the 9vHPV vaccine (2). Yearly, there are over 500,000 women worldwide that are 
diagnosed with cervical cancer (74). The estimated incidence of cervical cancer standardized 
by age is 14 per 100,000 individuals worldwide (74). Though there is variation by region: the 
rate has been estimated to be 27 cases per 100,000 women in Africa whereas it was 11 cases 
per 100,000 women in Europe (74). 
1.4 CERVICAL SCREENING IN SWEDEN 
Cervical screening was first introduced in Sweden in the 1960s. Since then the incidence of 
squamous cell cancer has dropped significantly; the incidence of cervical cancer in Sweden 
was around 20 cases per 100,000 women in 1968 and has dropped to around 7 cases per 
100,000 women since (74,75). Screening does not seem to have as strong an effect on 
adenocarcinoma; the incidence of adenocarcinoma has not decreased since the introduction of 
cervical screening (75). Cervical cancer now is the 12
th
 most common female cancer in 
Sweden, but remains the 4
th
 most common cancer in women worldwide (74,76). The first 
national screening recommendations were issued in 1985 by the National Board of Health 
and Welfare. All women between ages 20 and 59 were recommended to attend screening 
once every 3 years (77). New national guidelines for cervical screening were issued in 1998; 
the age to start screening was increased to 23, and women between the ages of 51 and 60 
years were recommended to attend screening once every 5 years (77). A switch to primary 
HPV testing has recently been recommended for all women at screening ages except for those 
23 to 29 years old, where screening every 3
rd
 year with cytology will continue. Women at 
ages 30 to 49 years will be screened every 3
rd
 year with HPV testing, and women ages 50 to 
64 years will be screened every 7
th
 year with HPV testing. HPV-positive women are followed 
up with cytology, whereas HPV-testing is used for triage in women with low grade squamous 
intraepithelial lesions (LSIL) when cytology is the primary test. In addition to the HPV-test, 
cytological co-testing will be done in women that come in for cervical screening at around 
age 41 (78). 
1.5 HPV VACCINATION IN SWEDEN 
HPV vaccination became available in Sweden in the fall of 2006. Girls could get HPV 
vaccinated with the qHPV vaccine and, as of the fall of 2007, girls also could get HPV 
vaccinated with the bHPV vaccine. Starting in 2007, both the bHPV and qHPV vaccines 
were included in the National Pharmaceutical Product insurance program for girls ages 13 to 
17. The National Pharmaceutical Product insurance program ensures that individuals do not 
have to pay more than 1800 SEK for drugs included in the program over a 12 month period 
(79). Girls that were outside this target age group of ages 13 to 17 were not eligible for 
reimbursement. From 2006 to 2012, vaccination was opportunistic in Sweden and the 
vaccination coverage remained rather low (around 25% for girls ages 13 to 17) (80). The 
National Board of Health and Welfare decided that, as of January 2010, HPV vaccination 
should be included in the childhood immunization program targeting girls at ages 10 to 12 
years. An additional catch-up vaccination program was launched for girls at ages 13 to 18 
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years. The implementation of the programs experienced a delay due to an extended tendering 
process. After a renewed tender and three appeals, the qHPV vaccine won the tender in 
November 2011 and the school-based vaccination program was operative from 2012. The 
vaccination coverage within the organized school-based program has reached 80%, and is 
around 60% for girls that were vaccinated in the catch-up HPV vaccination program (81). As 
of January 2015, the policy was updated and girls ages 9-13 years are now HPV vaccinated 
based on a two dose schedule. Individuals outside the target age group (9 to 13 years) 
continue to get vaccinated with a three dose vaccination schedule. 
Along with the introduction of HPV vaccination in Sweden, a national epidemiologic 
surveillance program of HPV vaccination was established. This surveillance work-plan was 
outlined by the Public Health Agency of Sweden (82). The program concerns the surveillance 
of HPV-related disease outcomes, seroepidemiology, and vaccination coverage. This 
information is of importance to confirm findings from clinical trials, but also to monitor the 
vaccination coverage, and obtain information on possible herd protection, HPV type 
replacement, and duration protection of the vaccine (82). 
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2 AIMS 
The studies included in this thesis examined the population-level effect of HPV vaccination 
on incidence of HPV-related disease outcomes, and attendance to cervical screening 
following vaccination. 
The specific study aims were: 
Study 1: To examine the association between qHPV vaccination and first occurrence of 
condyloma in relation to vaccine dose in a population-based setting. 
Study 2: To measure attendance to cervical screening after opportunistic HPV-vaccination. 
Study 3: To examine the association between qHPV vaccination and first occurrence of 
cervical intraepithelial neoplasia (CIN) stage 2 or worse (CIN2+) and CIN stage 3 or worse 
(CIN3+) in a population-based setting. 
Study 4: To assess incidence of condyloma following the introduction of qHPV vaccination 
in Sweden. 
 
  9 
3 MATERIAL AND METHODS 
3.1 DATA SOURCES AND COLLECTION 
Studies I, II, III, IV were part of the long-term evaluation of the effect of HPV vaccination 
and safety for which ethical approvals were granted by the regional Ethical Review Board in 
Stockholm. The Swedish national quality and health data registers were used for the data 
collection for the studies included in this thesis. According to Swedish regulation, informed 
consent by the study participants is not required for the utilization of register-based data for 
research purposes (83). 
All individuals that are resident in Sweden, for at least one year, have a personal identity 
number (PIN) (83). The Swedish national health data registers include individual-level data 
and the PIN is an important variable that can be used for data linkage between the registers. 
The National Board of Health and Welfare and Statistics Sweden are authorities that perform 
data linkages. Once a data linkage has been completed, the PIN is replaced by a study ID 
number. This is done to protect the integrity of personal data included the healthcare registers. 
3.1.1 Demographic registers 
All individuals that are resident in Sweden are registered with a PIN in the Total Population 
Register (TPR) which was established in 1968 and is held by Statistics Sweden. It includes 
basic information such as name, address, place of residence, sex, age, civil status, citizenship, 
country of birth, place of residence, and family relations between parents or parents and 
child(ren) (84,85). The Migration Register, including information on domestic moves, 
immigration, and emigration, and Multigeneration Register (MGR), containing information 
on an individual’s biological and/or adoptive parents, are both extracted from the TPR (86). 
The Longitudinal Integration Database for Health Insurance and Labour Market Studies 
(LISA) was first created in 1990. Updates are released annually. LISA is a rich data source 
containing e.g. information on participation in the labor market, education, and income of all 
individuals 16 years or older (87). For the studies included in this thesis, data extraction was 
limited to information on education level and disposable income. 
The National Causes of Death Register (CDR) contains information on all deceased 
individuals that were registered as living in Sweden. The CDR was established in 1952 by 
Statistics Sweden, and was migrated to the National Board of Health and Welfare in 1994 
(88).  
3.1.2 National Patient Register (NPR) 
The NPR was created in the mid-1960s by the National Board of Health and Welfare, and 
contained, at that time, only inpatient registration from public hospitals in selected counties. 
Since 1987 NPR has national coverage for inpatient somatic hospitalizations and from 1997 
and onwards outpatient somatic care is included from selected counties. Outpatient care was 
systematically included starting in 2001 (84). Diagnoses are reported to the NPR using the 
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International Classification of Diseases (ICD) with the 10
th
 revision of ICD in use since 1997 
(89,90). Cases of cervical cancer and cervical lesions can also be identified from the patient 
register. However, a distinction by histological cell type, i.e. squamous or glandular cells, 
cannot be made. 
3.1.3 Prescribed Drug Register (PDR) 
The PDR is an automated register containing information on drug prescriptions dispensed at 
pharmacies in the entire country and has complete national coverage since its start in July, 
2005. The National Board of Health and Welfare is responsible for the PDR. Drugs sold 
over-the-counter and inpatient prescriptions are not registered in the PDR. Drugs used in 
ambulatory care but administered at out-patient care are only partially registered. Drug 
prescriptions, including vaccine prescriptions, are entered in the PDR using Anatomical 
Therapeutic Chemical (ATC) codes (91,92). 
3.1.4 Swedish HPV Vaccination Register (SVEVAC) 
SVEVAC is a voluntary reporting system that was initiated by the former Swedish Institute 
for Communicable Disease Control (SMI), nowadays the Public Health Agency of Sweden. 
The register initially started in 2002 as a pilot project in three Swedish counties to register 
childhood vaccinations. Along with the introduction of HPV vaccination in Sweden in 2006, 
SVEVAC became a nationwide register for registering HPV vaccinations. Early comparisons 
between the sales figures and the number of vaccine doses registered in SVEVAC have 
shown register coverage of 85-90% (81). Since 2015 SVEVAC is run by the Swedish 
Association of Local Authorities and Regions (SKL). 
Registration in SVEVAC requires the informed consent of the vaccinated individual or their 
parent. Vaccinations where informed consent is not obtained will be registered in SVEVAC 
anonymously. Information on sex, birth year, date of vaccination are still available, but the 
information cannot be linked to other registers as the PIN is missing. This means that it is not 
known which information belongs to one or several persons, i.e. whether an individual has 
multiple vaccine dose registrations or not. In 2012, the rate of anonymous registrations 
increased in some counties due to changes to the informed consent form made at the 
municipality level, i.e. a change from opt-out informed consent to opt-in informed consent, 
and changes to the online data entry form. Subsequently, the informed consent was changed 
back to an opt-out. 
3.1.5 National Vaccination Register (NVR) 
From 2013 a Swedish vaccination register for child vaccinations (up to and including age 12) 
was started by the Public Health Agency of Sweden (93). The NVR is a health data register 
with mandatory reporting. It includes all childhood vaccinations that are part of the national 
immunization program. Individuals vaccinated outside the childhood vaccination program, 
i.e. girls born before 1999 and boys, are registered in SVEVAC. Registration with PIN is 
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obligatory in the NVR and all HPV vaccinations in the school-based program are included 
since 2013. 
3.1.6 Swedish National Cervical Screening Registry (NKCx) 
The Swedish National Cervical Screening Registry, NKCx by its Swedish acronym, is a data 
quality register and contains information on all cytological and histological samples taken in 
the country as well as all invitations issued for cervical screening. NKCx has complete 
national coverage since the mid-1990s though cytology and histology data are available for 
some counties back to the early 1970s. Data on issued invitations to screening has been 
recorded since the mid-1990s and has been complete since 2008 (80,94). Results from 
cytology and histology are entered in NKCx according to the systematized nomenclature of 
medical diagnoses (SNOMED). This SNOMED coding is translated according to the 
Swedish standard cytology nomenclature at NKCx (94). 
3.1.7 Swedish Cancer Register (SCR) 
The National Board of Health and Welfare is responsible for the SCR. All newly detected 
cancer cases in Sweden have been registered since its start in 1958. It is mandatory for 
healthcare providers to report all new cases of cancer to the register. Three different types of 
data are stored in the SCR, namely: patient data, medical data, and follow-up data. The 
medical data includes detailed information on tumor characteristics such as the tumor site, 
tumor type, histological type, and staging (95,96). Since 2005, the site and type of the tumor 
have been characterized using ICD for oncology version 3 (ICD-O/3). However, 
characterization of the site and type of the tumor using ICD 7
th
 revision and the WHO C24 
histopathological code is available for the entire period starting in 1958 (96,97). Based on a 
comparison with the NPR, the overall underreporting of malignant cancer cases to the cancer 
register was estimated to be 3.7% in 1998; the rate varies by cancer site and was estimated 
3.4% for cancers of the female genital organs (95). For cervix uteri also all cases of CIN3 
including cancer in situ are registered. 
3.2 EXTRACTION OF VACCINATION EXPOSURE FROM MULTIPLE 
REGISTERS  
There are three data registers that include information on HPV vaccination: PDR, SVEVAC, 
and the NVR. During the opportunistic vaccination period (2007-2011) vaccinations were 
registered in SVEVAC. The majority of these vaccinations were also registered in the PDR 
since reimbursement for the HPV vaccine could only be obtained if vaccine doses were 
dispensed at the pharmacy. Individuals that directly purchased the vaccine and were 
subsequently vaccinated at a vaccination center are not registered in the PDR. HPV 
vaccinations as part of the school-based program (2012 and onwards) have been registered in 
SVEVAC, and from January 1
st
, 2013, all childhood vaccinations have been registered in the 
NVR. 
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The main exposure for studies I, II, and III is HPV vaccination. SVEVAC was used as the 
main source to obtain vaccination data. As in SVEVAC, the records in the NVR represent the 
actual vaccination date, and in study III, data were merged to the vaccination dates obtained 
from SVEVAC. The completeness of SVEVAC varies over the course of the study and 
incomplete vaccination records (individuals vaccinated with 1 or 2 doses) were therefore 
complemented with vaccine dispensation dates from PDR. Vaccine dispensation dates were 
identified with ATC codes J07BBM01 and J07BBM02 for the qHPV and bHPV vaccines, 
respectively. This was done using an algorithm where dispensation dates occurring directly 
after or more than 14 days prior to the vaccination administration date were considered as 
new doses. Studies I and III only utilize qHPV vaccination data to define vaccination status. 
As the purpose of study II was to assess screening attendance after HPV vaccination, 
irrelevant of the vaccine used, both bHPV and qHPV vaccines were included to define HPV 
vaccination status. Data from the NVR was only utilized in study III as this register only 
includes HPV vaccinations from 2013 and onwards and study follow-up in study I and II 
ends in 2010 and 2012, respectively. 
3.3 STUDY OUTCOMES 
3.3.1 Condyloma 
First occurring cases of condyloma were included as the study outcome in study I. For study 
IV, both first occurring and subsequent cases of condyloma were used to define the study 
outcome. Cases of condyloma were identified via the NPR by using the 10th revision of the 
ICD code A63.0 and dispensations of pharmaceuticals podophyllotoxin and imiquimod were 
taken from the PDR using the corresponding ATC codes D06BB04 and D06BB10. The 10
th
 
revision of the ICD code A63.0 is exclusively used to specify a diagnosis of condyloma. 
Podophyllotoxin is solely used to treat condyloma; however, imiquimod is also used to treat 
superficial basal cell carcinoma and actinic keratosis which are more likely to occur later in 
life (98–100). Individuals can have multiple records in the NPR and/or PDR related to one 
episode of condyloma. Differentiation between subsequent cases of condyloma is not 
possible. Therefore in study IV, a new subsequent case of condyloma was defined if there 
were no other condyloma-related hospital visits and no pharmaceuticals were prescribed for 
treatment of condyloma in the previous 6 months. 
3.3.2 Attendance to cervical screening 
Attendance to cervical screening was the study outcome in study II. All issued invitations 
were identified via NKCx. Attendance to cervical screening was defined as the first cytology 
taken after an invitation was issued. Women eligible for cervical screening, i.e. at ages 23 to 
60, receive invitations to attend cervical screening. The first invitation to screening is sent to 
women at age 23, though some counties send invitations the year a woman turns 23 meaning 
that these women can receive an invitation and go to screening at age 22. New invitations to 
screening are issued after three years since the last registered cytology for women ages 23 to 
50. For women ages 51 to 60, new invitations are issued five years after the last registered 
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cytology. Yearly reminders are sent to women that do not attend screening following an 
invitation.  
3.3.3 Cervical lesions 
The study outcomes of study III include first occurrence of a histological diagnosis of CIN2+ 
and CIN3+. Lesions with non-squamous origin, such as adenocarcinoma in situ (AIS) and 
adenocarcinoma, were also included in the outcomes CIN2+ and CIN3+. Diagnoses were 
identified via NKCx and the SCR based on the corresponding SNOMED codes and ICD 7th 
revision, 171 for cervical cancer, respectively. Table 1 shows the SNOMED codes, and their 
explanations, included in the outcomes CIN2+ and CIN3+. 
Table 1. Diagnoses included in the outcomes CIN2+ and CIN3+ as identified from NKCx. 
SNOMED Explanation 
Histological diagnosis 
CIN2+ CIN3+ 
M74007 Cervical Intraepithelial Neoplasia grade 2 X  
M80702 Cervical Intraepithelial Neoplasia grade 3 X X 
M80702 Carcinoma in situ X X 
M81402 Adenocarcinoma in situ X X 
M85602 Adeno-squamous cancer in situ X X 
M80703, M81401, 
M81403, M85601, 
M85603, M80413 
Invasive cancer of any origin (squamous-cell 
carcinoma, adenocarcinoma, adeno-squamous 
carcinoma, small cell carcinoma) 
X X 
3.4 STUDY DESIGN 
3.4.1 Register-based cohort study design 
Register-based cohort study designs were used for studies I, II, and III. In studies I and III the 
effect of vaccination in the population was assessed. A cohort of women ages 10 to 24 years 
(study I) and ages 10 to 29 years (study III), representing the entire female population 
resident in Sweden at some point in time during the study period, was followed for HPV 
vaccination and the disease outcome. As the HPV vaccines are prophylactic, all women that 
were diagnosed with the outcome prior to study inclusion were excluded. In study II, 
screening attendance after HPV vaccination was measured. The study base included a birth 
cohort of women born between 1977 and 1987 years that were invited to organized cervical 
screening at some point during the study period. 
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3.4.2 Ecological study design 
An ecological study design was used for study IV to examine changes in condyloma 
incidence prior to and after HPV vaccine availability. Cases of condyloma were collected by 
calendar year and 5-year age-groups. In contrast to the register-based cohort approach in 
studies I, II, and III, where individual-level data was used, aggregated data was collected. 
Within an ecological study design, the exposure status is not linked to the outcome. 
Furthermore, data are analyzed at the population level rather than the individual level. 
3.5 STUDY POPULATIONS 
3.5.1 Study I 
Data on vaccination, cases of condyloma, education level, and demographic information were 
merged with the source population comprising all girls and young women ages 10 to 24 years 
old (Figure 1a). The study period was between January 1, 2006 and December 31, 2010. 
Individuals were followed from their 10
th
 birthday or start of follow-up until the event of 
interest or one of the censoring criteria was reached, i.e. bHPV vaccination, death, 
emigration, age 25, or the end of the study period. Individuals that were diagnosed with 
condyloma prior to individual start of study follow-up were excluded. 
3.5.2 Study II 
Figure 1b shows the data that were utilized to construct the study population including 
women born between 1977 and 1987 that were invited to cervical screening. The study period 
started on October 1, 2006 and ended on December 31, 2012. The birth cohort was followed 
from invitation to cervical screening during the study period to attendance or one of the 
censoring criteria: death, emigration, or the end of the study period. 
3.5.3 Study III 
Information on vaccination, diagnoses of cervical lesions, education level, and demographic 
data were obtained from the Swedish quality and healthcare data registers and were merged 
to the source population comprising of all girls and young women at ages 13 to 29 (Figure 
1c). The study period started on January 1, 2006 and ended on December 31, 2013. 
Individuals were followed from their 13
th
 birthday or start of follow-up until the event of 
interest, i.e. CIN2+ or CIN3+, or when one of the censoring criteria was reached, i.e. bHPV 
vaccination, death, emigration, age 30, or the end of the study period. 
Two additional sub-populations consisting of (a) women at pre-screening ages and (b) 
women at screening ages were defined. Women in the pre-screening population entered the 
study on their 13
th
 birthday or the start of follow up, in case they were older than 13 years at 
the start of follow-up, and were followed until the event of interest, or one of the previously 
defined censoring points, age 23, or first invitation to cervical screening. Women at screening 
ages entered the study after a normal cytology taken at cervical screening ages or on January 
1, 2006, if they have attended cervical screening within 3.5 years prior to study inclusion. 
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Follow-up ended at the outcome of interest, one of the predefined censoring criteria, an 
abnormal cytology not confirmed by histology, or 3.5 years after a normal cytology. 
Individuals diagnosed with the study outcome prior to the start of individual follow-up were 
excluded.  
3.5.4 Study IV 
Figure 1d shows the data sources that were utilized to identify new cases of condyloma and 
the mid-year population estimates of all men and women ages 15 to 44 years in Sweden, i.e. 
the TPR, NPR and PDR. The study period was between January 1, 2006, and December 31, 
2012. Summary statistics on number of cases and mid-year population by year, sex, and age 
were obtained. 
 
Figure 1. Data used to create the study populations in (A) study I; (B) study II; (C) study III; and (D) 
study IV. 
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3.6 STATISTICAL METHODS 
3.6.1 Survival analysis 
The data in studies I, II, and III are time-to-event data; individuals were followed from study 
entry to study exit due to either an event or study censoring. The number of cases occurring 
and person-time in the study were collected and analyzed using survival analysis. The 
incidence rate (IR) can be calculated as the number of cases divided by the number of person-
years. The incidence rate ratio (IRR) can be obtained by dividing the IR among the exposed 
by the IR among the unexposed. 
Rate ratios, adjusted for education level of the parents, comparing the effect of vaccination 
with non-vaccination on disease incidence, were estimated with survival analyses using a 
Poisson regression model for studies I and III, and Cox proportional hazards model for study 
II. The IR and IRR are estimated using a Poisson regression model. The hazard and hazard 
ratio (HR) can be calculated from a Cox proportional hazards model. The hazard and HR can 
be interpreted as the IR and IRR. Poisson regression is a parametric model, assuming 
constant rates over time whereas the Cox model is a semi-parametric model that makes no 
assumption on the shape of the baseline hazard over time. Both models assume proportional 
hazards, meaning that the hazards among exposed and unexposed should be proportional over 
time. 
Studies I, II, and III, use attained age as the underlying time-scale. The rate of condyloma, 
cervical lesions, and screening attendance all depend on age, therefore, attained age was 
chosen as an underlying time scale. This means that for Poisson regression, different attained 
age categories were created, i.e. the individual could contribute person-time to several 
attained age-groups as the individual attains age during follow-up, which is subsequently 
included in the Poisson regression model. Within each age-category, a constant rate of 
disease is considered, but the rate can vary between age-categories. The splicing of attained 
age is automatically done in the Cox proportional hazards model, and does not need to be 
included in the model. The baseline hazard is not directly estimated from the model. 
Some individuals were already vaccinated at the start of individual follow-up, whereas others 
got vaccinated during follow-up, and others do not get vaccinated during follow-up. The 
exposure variable HPV vaccination may change over time, therefore it can be considered as a 
time-varying exposure. In study I, exposure changed after vaccination with dose one, two, 
and three creating four groups: unvaccinated, partially vaccinated with dose one and dose 
two, and fully vaccinated (Figure 2), In study II exposure status changed from unvaccinated 
to vaccinated when an individual got vaccinated with at least one dose (Figure 3). In study III 
the exposure status changed from unvaccinated to vaccinated if three-dose vaccination was 
achieved (Figure 4). Depending on the number of doses received, the same individual could 
contribute person-time to multiple exposure groups (Figures 2-4). 
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Figure 2. Vaccination per dose level as a time-varying exposure in study I. 
 
Figure 3. Vaccination with at least one dose as time-varying exposure in study II.  
 
Figure 4. Vaccination with three doses as a time-varying exposure in study III.  
3.6.2 Study I 
Study I reports crude IR:s with 95% confidence intervals (CI:s) reported per 100,000 person-
years by attained age, age at vaccination initiation, and vaccine dose were calculated. Two 
age at vaccination initiation groups (<17, 17-19 years) were created based on the median age 
of sexual debut (101). IRR:s, comparing the effect of vaccination per dose level with the 
unvaccinated, were estimated using a regression model with a Poisson distribution adjusting 
for parental education level with attained age as the underlying time-scale, and vaccine dose 
as a time-varying exposure (Figure 2). IRR:s were calculated both stratified on age at 
vaccination initiation, and for all vaccination initiation ages combined. Based on this Poisson 
model, incidence rate differences (IRD:s) averaged across the levels of attained age and 
parental education were estimated between vaccine doses. 
To properly evaluate dose effectiveness in a population setting, ideally, only women not 
HPV-infected at the start of vaccination for which outcome of clinical disease is assessed 
should be included. However, in a population setting, it is often not feasible to obtain 
information on HPV infection status at vaccination initiation. As condyloma has an 
incubation period of 1-6 months (57–59), those who have a prevalent infection at the time of 
vaccination will be more likely to have their diagnosis shortly after vaccination, i.e. after one 
or two doses of the vaccine. Estimates of the incidence of condyloma following vaccination 
with one, two, or three doses may be biased towards a higher incidence of condyloma after 
vaccination with dose one and two. In study I, prevalent infections were accounted for by 
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introducing buffer periods of three months following vaccination with dose one, two, and 
three. The first 3 months following vaccination with a vaccine dose are included in previous 
exposure-state(s) (Figure 5). 
 
Figure 5. Illustration of buffer-period principle study I. 
To estimate a realistic length of the buffer period, the cumulative incidence proportion (1-
Survivor function) of condyloma after one dose was calculated. The corresponding 
cumulative incidence proportion for the unvaccinated based on age during follow-up was 
calculated and the effect of age was averaged according to the age-at-first-vaccination 
distribution. This is functionally equivalent to the graphical method for visualizing selection 
bias suggested in Törner et al. 2011 (102), but using a different scale for the hazard and a 
non-parametric estimate instead of flexible parametric models. 
3.6.3 Study II 
In study II, we estimated the cumulative incidence proportion of women attending cervical 
screening following an invitation to cervical screening in vaccinated and unvaccinated 
women. Women in this study were considered vaccinated after vaccination with at least one 
dose of either the bHPV or qHPV vaccine. Data were further analyzed using a Cox 
proportional hazards model with attained age as the underlying time-scale and vaccination as 
time-varying exposure. The proportional hazards assumption was tested based on a plot of the 
Schoenfeld residuals. Model fit was assessed when adjusting for education level and income 
of the study participant or the parent using the Akaike Information Criterion (103). The 
model that best fitted the data included adjustments for individual education level and 
individual income. The model fit including adjustments for other socio-economic variables 
parental education level and parental income did not result in a better model fit. 
The relation between vaccination and attendance to screening was assessed over the entire 
study period, but was also assessed for the first and second screening round separately to 
assess whether screening attendance changed over time. Therefore, women were censored 
after three years of non-attendance in screening round one. Women entered the second 
screening round at the first invitation to cervical screening following attendance to cervical 
screening in round one or after three years of non-attendance. Attendance to screening round 
two was also estimated in only those that attended screening in round one. 
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3.6.4 Study III 
In study III we estimated the effect of three-dose qHPV vaccination on incidence of CIN2+ 
and CIN3+ in the total population. Crude IR:s with 95%CI:s were reported by attained age, 
age at vaccination initiation, and vaccination exposure. Adjusted IRR:s with 95%CI:s were 
estimated using a Poisson regression model adjusting for parental education level with 
attained age as an underlying time-scale and qHPV vaccination with three doses handled as a 
time-varying exposure. Cervical lesions are a screen-detected outcome, therefore, the 
diagnosis can only be made if women attend screening. The same analysis was done in a 
screened population where lesions detected approximate lesions present. The same analysis 
was also carried out in the population at pre-screening ages. 
There is a diagnostic time lag between the time a cytology was taken and when a colposcopy 
(histology) takes place. The lesion can progress into a CIN2+ or CIN3+ lesion during this 
diagnostic time lag, or the CIN2+ or CIN3+ lesion may already be present at the time of the 
cytology. In both instances, it is likely that the woman is already infected with HPV at the 
time of cytology. To correct for this diagnostic time lag, a backdating principle was adapted 
where 6 months was subtracted from the date on which a histologically confirmed CIN2+ or 
CIN3+ case was diagnosed. 
3.6.5 Study IV 
Study IV estimated the burden of condyloma following the introduction of qHPV 
vaccination. Mid-year estimates by age were calculated for year X by multiplying the sum of 
the population counts within a 5-year age-group for year X and year X-1 with 0.5. The mid-
year population counts were taken as a proxy for person-years for the calculation of the IR:s 
by 5-year age-groups, calendar year, and sex. Mid-year counts of the vaccinated population 
were calculated as well. 
The IR:s with corresponding 95%CI:s were calculated using a Poisson regression model 
stratifying on sex and age. A Poisson regression model was also used to calculate IR:s with 
95%CI:s based on a model with a spline term to adjust for calendar year (natural cubic spline, 
3 knots), stratified by age and sex. A broken-line regression model based on the log rates of 
condyloma was fit to estimate the annual percent change (APC) and 95%CI:s and average 
APC (AAPC) within a given period (104). Three different periods were created 2006-2007, 
2008-2009, 2010-2012 over which the AAPC was calculated. These periods were chosen to 
represent three periods with increasing levels of HPV vaccination exposure. Only a few 
individuals were vaccinated during period 2006-2007, and this period was therefore 
considered to represent a pre-vaccination period. A greater proportion within the target age-
group was vaccinated between 2010 and 2012, whereas the vaccination levels were 
considerably lower during 2008 and 2009, hence different periods were defined. 
The underlying transition point that best fitted the data was obtained by using an optimizing 
method based on a combination of a grid search and golden section search. Where the golden 
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section search reached a local minimum, the best fitted model obtained via the grid search 
was selected.  
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4 MAIN FINDINGS 
4.1 STUDY I 
In study I, the risk for condyloma after qHPV vaccination per dose level was estimated by 
including 1,046,165 individuals that contributed 3,995,631 person-years. Of the 115,197 
individuals that started qHPV vaccination, 89,836 continued to receive dose 2 and 3 of the 
qHPV vaccine and thereby completed qHPV vaccination. A total of 20,383 individuals were 
diagnosed with condyloma during follow-up of which 76, 79, and 167 cases were in 
individuals vaccinated with 1, 2, and 3 doses of the qHPV vaccine, respectively. 
Figure 6 shows the cumulative incidence proportion of condyloma by vaccination status. 
Initially, no differences were seen in cumulative incidence proportion by vaccination status. 
At around ~3 months, the cumulative incidence proportion of those vaccinated leveled off 
compared those unvaccinated. 
 
Figure 6. Cumulative incidence proportion of condyloma in vaccinated and unvaccinated individuals 
(JAMA 2014; Herweijer et al.; Figure 1).  
Overall, the highest rates of condyloma were seen amongst those unvaccinated (IR=528, 
95%CI=520-535). Vaccination with 1, 2, and 3 doses of the qHPV vaccine resulted in lower 
rates of condyloma with each additional dose. The corresponding rates were 273 
(95%CI=218-342), 174 (95%CI=139-217), and 138 (95%CI=119-161) cases of condyloma 
per 100,000 person-years. This pattern, where an additional vaccine dose resulted in a lower 
crude IR, was seen across all attained age categories (Figure 7).  
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Figure 7. Crude incidence rates of condyloma per attained age-group and dose (JAMA 2014; 
Herweijer et al.; adapted from Table 2) (* represent truncated upper error bar). 
Vaccination with one, two, and three doses was associated with a significant reduction in risk 
for condyloma. The greatest reduction was seen after three-dose vaccination with observed 
reductions of 82% (IRR=0.18, 95%CI=0.15 to 0.22) and 77% (IRR=0.23, 95%CI=0.18 to 
0.29) in girls initiating vaccination at ages 10-16 years and at ages 17-19 years, respectively. 
The three versus two-dose comparisons were significant in both girls initiating vaccination at 
ages 10-16 years and 17-19 years with corresponding reductions of 37% (IRR=0.63, 
95%CI=0.43 to 0.93) and 34% (IRR=0.66, 95%CI=0.45 to 0.95). Corresponding differences 
in number of prevented condyloma cases per 100,000 person-years were 59 (95%CI=2 to 
117) and 67 (95%CI=3 to 132) cases.  
The current analyses included both individuals that completed their three-dose vaccination, 
and those that started vaccination but did not continue to receive all three recommended 
doses of the qHPV vaccine. Individuals who complete three-dose vaccination might differ 
from those that do not complete three-dose vaccination in terms of risk of acquiring an HPV 
infection. Therefore, we compared the effect of receipt of two doses of the qHPV vaccine in 
those that did and did not complete three-dose vaccination and found no difference in risk for 
condyloma (IRR=0.88, 95%CI=0.53 to 1.44).  
4.2 STUDY II 
The results in study II showed that vaccinated women were equally likely, if not more likely 
(HR=1.05, 95%CI=1.02 to 1.08), to attend cervical screening during follow-up. These results 
were based on a study population comprising 629,703 women that received an invitation to 
cervical screening during follow-up of which 4,897 (0.8%) women were vaccinated during 
the study period. The majority of the women were vaccinated after age 19; hence they were 
opportunistically vaccinated without receiving reimbursement.  
The screening attendance three years after invitation to screening, measured as the cumulative 
incidence proportion, was 86% in vaccinated individuals and 75% in unvaccinated 
* * 
* 
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individuals. This difference in screening attendance among vaccinated and unvaccinated 
women started shortly after invitation to screening and was present throughout the study 
period (Figure 8). A temporary small increase in screening attendance was seen in both 
vaccinated and unvaccinated women at 12 and 24 months (black arrows Figure 8), which 
most likely represents renewed invitations to attend cervical screening, issued annually  to 
non-attenders.  
 
Figure 8. Cumulative incidence proportions of screening attendance since first invitation to screening 
by vaccination status (PlosOne 2015; Herweijer et al.; Figure 3). 
The HR, without adjustments made for income and education level, comparing screening 
attendance between vaccinated and unvaccinated individuals was 1.28 (95%=CI 1.24 to 
1.32). After adjustments were made for income and education level, vaccination status was 
associated with a higher cervical screening attendance overall and by screening round 
(HR=1.05, 95%CI=1.02 to 1.08), round 1 (HR=1.09, 95%CI=1.05 to 1.13), and round 2 
(HR=1.15, 95%CI=1.10 to 1.20). Screening attendance among those vaccinated and 
unvaccinated by education level showed that vaccinated women with missing education level, 
less than high school, high school, and university education were equally or more likely to 
attend screening as compared to unvaccinated women. Differences in cervical screening 
attendance among vaccinated and unvaccinated women seem to increase if education level 
was lower which was seen in both the overall analysis and analyses by screening round.  
4.3 STUDY III 
In study III, the impact of qHPV vaccination on risk for cervical lesions was estimated by 
including 1,333,691 girls and young women that contributed 7,252,096 person-years of 
which 236,372 individuals were vaccinated contributing 604,454 person-years. The majority 
(88%) of the individuals who had a histological diagnosis of CIN2+ had the diagnosis within 
6 months after the abnormal cytology, hence a diagnostic time lag of 6 months was chosen 
(Figure 9). 
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Figure 9. Frequency distribution of time between last smear prior to histologically confirmed 
diagnosis of CIN2+ (From Herweijer et al., Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions 
by age at vaccination: A population-based study, Suppl Figure 3, Int J Cancer 2016. Copyright © 2016 by John Wiley Sons, 
Inc. Reprinted by permission of John Wiley & Sons, Inc.)  
Prior to the start of cervical screening, low rates of both CIN2+ and CIN3+ were observed. 
Peak crude rates of CIN2+ and CIN3+ were seen in women at ages 22-23, which was in 
accordance with the start of cervical screening. The crude IR per 100,000 person-years of 
CIN2+ and CIN3+ among vaccinated individuals was lower than the crude IR seen among 
unvaccinated individuals, with lower rates of CIN2+ and CIN3+ seen in individuals initiating 
vaccination at a younger age. This observation was seen across all attained age-categories 
(Figure 10). 
The results from the Poisson regression models adjusting for attained age and education level 
were in line with the observations seen in the crude data. Vaccination was associated with a 
significant reduction in risk for both CIN2+ and CIN3+ at all vaccination initiation ages. 
Greatest reductions in CIN2+ and CIN3+ were seen in girls that initiated vaccination <17 
years of 75% (IRR=0.25, 95%CI=0.18 to 0.35) and 84% (IRR=0.16, 95%CI=0.08 to 0.32), 
respectively. The reductions in risk for CIN2+ and CIN3+ decreased with increasing age at 
vaccination initiation, but the reductions remained significant. Similar results were seen when 
restricting the analyses by only including screened person-years, i.e. women that recently 
attended the organized cervical screening program. No cases were observed among women 
that initiated vaccination prior to age 17. Compared to no vaccination, vaccination was 
associated with lower rates of CIN2+ of 88% (IRR=0.12, 95%CI=0.02 to 0.85) in individuals 
17-19 years at vaccination initiation. For those ages 20-29 at first vaccination, a reduction in 
risk of CIN2+ of 21% (IRR=0.79, 95%CI=0.56 to 1.12) was observed, but did not reach 
statistical significance. Similar reductions in risk of CIN3+ of 77% (IRR=0.23, 95%CI=0.03 
to 1.64) and 23% (IRR=0.77, 95%CI=0.48 to 1.24) were observed in individuals initiating 
vaccination at ages 17-19, and 20-29, respectively. These results did not reach statistical 
significance, most likely due to limited follow-up time. This analysis did not include person-
time of individuals that were under-screened, and therefore, lesions detected provide a good 
estimation of lesions present. 
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Figure 10. Crude incidence rates of (A.) CIN2+ and (B.) CIN3+ per attained age-group and age at 
vaccination initiation category (From Herweijer et al., Quadrivalent HPV vaccine effectiveness against high-grade 
cervical lesions by age at vaccination: A population-based study, adapted from Table 2, Int J Cancer 2016. Copyright © 2016 
by John Wiley Sons, Inc. Reprinted by permission of John Wiley & Sons, Inc.) 
4.4 STUDY IV 
Disease surveillance, both prior to and post vaccine availability, play an important role in the 
follow-up of both the effect of vaccination on burden of HPV-related disease in vaccinated 
populations, as well as herd protection in unvaccinated populations. Study IV aimed to 
monitor condyloma incidence by means of an ecological study design. In this study, 
vaccinated girls were mainly opportunistically vaccinated at ages 13 to 17 years. During the 
course of the study, estimated vaccination coverage in girls at ages 15 to 19 years increased to 
41.1% in 2012. This is the group where direct effects of vaccination are expected. A change 
in trend of condyloma incidence was observed at year 2008.6 resulting in an AAPC of -
13.1% (95%CI=-14.8 to -11.4) for period 2008-2009 and -18.5% (95%CI=-21.3 to -15.8) for 
period 2010-2012 (Figure 11). Initially a slight increase in incidence was seen in the 
corresponding age-group for boys, but after 2009.8 a change in trend occurred, yielding an 
AAPC of -16.6% (95%CI=-19.9 to -13.2) for the period 2010-2012. As very few boys were 
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vaccinated, and the decreasing trend in incidence started approximately one year later than 
that of girls, these observed decreases in incidence of condyloma might suggest herd 
protection from vaccinated girls in the corresponding age-group (Figure 11). Vaccination 
coverage was considerably lower (14.1%) in the following age-category of young women 
ages 20 to 24, which most likely is composed of a mixture of young women vaccinated at 
ages 20 to 24, and girls that have been vaccinated prior to age 20 and aged into this age 
category during follow-up. For these women, there was initially no specific trend observed, 
but rates started to decrease from 2008.5 and onward (2010-2012: AAPC=-11.3%, CI=-12.7 
to -9.9) (Figure 11). We saw a similar pattern of declining incidence rates of condyloma, for 
men ages 20-24 (2010-2012: AAPC=-13.0%, CI=-15.2 to -10.9) which might also point 
towards herd protection. The incidence of condyloma decreased from 2006-2007 (AAPC= -
3.2%, CI=-4.7 to -1.7) to 2010-2012 (AAPC=-5.1%, CI=-6.6 to -3.6) for women ages 25-29, 
whereas a decrease in AAPC was seen in men for period 2010-2012 (AAPC=-8.8%, CI=-
13.2 to -4.3), only. For men and women ages 30 and above, there were no signs of decreasing 
incidence of condyloma over time.  
 
Figure 11. Fitted broken-line regression of incidence of condyloma by, calendar time, sex, and age. 
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5 METHODOLOGICAL CONSIDERATIONS 
The following section will discuss methodological considerations underlying studies I-IV in 
more detail and how these concerns were addressed.  
5.1 VACCINE UPTAKE AND SELF-SELECTION BIAS 
Most of the girls that were vaccinated during study follow-up in studies I, II, and III were 
opportunistically vaccinated. Girls at ages 13 to 17 were eligible for subsidized vaccination, 
whereas those not eligible for subsidized vaccination could only get HPV-vaccinated at their 
own expense. Individuals vaccinated within this period might therefore represent a selected 
group as they actively chose to get HPV-vaccinated and were willing to pay for the vaccine. 
Likewise, socio-economic mechanisms might have played a role. It has previously been 
shown that a parent’s education level is positively associated with vaccination status of their 
daughter(s) (105). Subsequently, the model in study I, II, and III was adjusted for level of 
education to account for such bias. 
Furthermore, individuals that actively chose to vaccinate might have been more health-
conscious in terms of healthcare seeking behavior. With regard to study I, differences in 
healthcare seeking behavior is expected to be non-differential by dose. In addition, a previous 
study tested the presence of self-selection bias, i.e. individuals that were at higher risk for 
development of condyloma were also more likely to be vaccinated, by comparing the rate of 
condyloma in the unvaccinated population before and after the qHPV vaccine was available. 
There was no indication that girls below the age of 20 vaccinated via the opportunistic 
vaccination program were self-selected, however, rates of vaccination in the unvaccinated 
population over age 20 declined over time which could indicate that women vaccinated over 
age 20 were self-selected, i.e. vaccinated women were at higher risk for condyloma (105). 
In study I, fully vaccinated girls might have been different from girls that were partially 
vaccinated with one or two doses of the qHPV vaccine in terms of life-style factors and might 
therefore be at greater risk for condyloma. There is no information on life-style factors, such 
as HPV status and the number of sexual partners, available in the national healthcare data 
registers. However, we did exclude women previously diagnosed with condyloma as a proxy 
for HPV status. Furthermore, we compared the effect of qHPV vaccination after two doses in 
girls that did complete three-dose vaccination with girls that did not complete three-dose 
vaccination and found no evidence of the presence of such a bias. 
If HPV-vaccinated women are also more likely to attend cervical screening, a higher 
screening attendance in vaccinated women will lead to a greater likelihood to detect cervical 
lesions as compared to women that were not vaccinated thereby rendering the vaccine less 
effective. Study II showed that the level of education explained part, but not all, of the 
increased likelihood of attending cervical screening after vaccination. With regard to study 
III, we performed an additional analysis in recently screened women accounting for under-
screening. Results were in line with the results on vaccination effectiveness observed in the 
total population. For the assessment of cervical screening attendance after HPV vaccination, 
 28 
we have only included women that were invited to the cervical screening program. Women 
that attend cervical screening with an interval of less than three years, which might be even 
more health conscious, were not captured as invitations to cervical screening are issued three 
years after the last attendance to screening for women with a normal test result. The invitation 
system integrates these opportunistic screening tests, delaying the next invitation to organized 
screening until the age-specific interval has passed (94). 
5.2 PREVALENT INFECTIONS VERSUS INCIDENT INFECTIONS 
The HPV vaccines are prophylactic and have no effect on the clearance of an infection or 
progression into a lesion (37,38). The study participants in the clinical trials were tested for 
HPV DNA, and information was available on whether participants were seropositive for one 
or more HPV types. Such data is usually not available in a population-based setting where 
little is known about prevalent HPV infections at the time of vaccination. It can be argued 
whether observed “vaccine failures” truly represent a vaccine failure or are the result of 
infections acquired prior to vaccination. 
For the studies presented in this thesis, it was not possible to obtain information on HPV 
status at the time of vaccination. The true effect of vaccination on condyloma incidence might 
therefore be underestimated in study I. We tried to correct for prevalent infections by 
introducing buffer-periods where case counting started three months after receipt of a vaccine 
dose in study I. A diagnostic time lag between abnormal cytology and confirmation of 
disease via histology was introduced in study III. Furthermore, vaccine effectiveness in study 
III was measured after three-dose vaccination, which means that there was approximately six 
months of partially vaccinated person-time that were included in the unvaccinated group. 
Cases occurring in that time-window, between vaccination initiation and completion, were 
most likely due to prevalent infections prior to start of vaccination. 
5.3 MISCLASSIFICATION OF CASES 
Pharmaceutical treatment with podophyllotoxin and imiquimod was used as a proxy for 
condyloma. Imiquimod can be prescribed to treat condyloma, but can also be prescribed to 
treat other skin modalities. The other treatment indications of imiquimod might have falsely 
attributed cases of condyloma to individuals that were treated with imiquimod. We have done 
a descriptive analysis on prescription patterns of imiquimod and podophyllotoxin for the 
period 2006-2012 by age. The podophyllotoxin prescriptions increase sharply at ages where 
condyloma incidence peaks after which the number of prescriptions sharply decreased. A 
similar, but lower, peak around age 20 is seen for the number of imiquimod prescriptions 
with a higher peak seen at older ages (Figure 12.). 
  29 
 
Figure 12. Number of prescriptions and loess smoothing line for pharmaceuticals imiquimod and 
podophyllotoxin registered to the PDR between 2006 and 2012 by age. 
The dispensations of pharmaceutical imiquimod as a proportion of the total expenditure of 
pharmaceuticals used for treatment of condyloma, i.e. podophyllotoxin and imiquimod, for 
period 2006-2012 as registered in the PDR is shown in Figure 13. The share of imiquimod 
prescriptions increases from age 20 to about age 65 from ~10% to almost 100%. This most 
likely reflects the increasing use of imiquimod to treat other skin abnormalities. 
 
Figure 13. Share (%) and loess smoothing line of dispensations of pharmaceutical imiquimod to total 
expenditure of pharmaceuticals used for treatment of condyloma (podophyllotoxin and imiquimod) 
for period 2006-2012 as registered in the PDR. 
The misclassification of falsely attributing condyloma cases to individuals treated with 
imiquimod was not considered an issue in study I, due to low upper age limit of the study 
population. However, in study IV, it might be considered an issue. Therefore, the upper age 
limit was set to 44 to minimize misclassification. Furthermore, not all cases of condyloma 
were captured in the registers; diagnoses made in private care settings that did not receive 
pharmaceutical treatment might have falsely misclassified individuals as healthy. Study IV 
includes both first occurring and subsequent cases of condyloma. 
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The outcome in study III was histologically confirmed diagnosis of CIN2+ or CIN3+. This 
diagnosis is, as mentioned earlier in this thesis, mainly detected via cervical screening. Those 
individuals with CIN2+ or CIN3+ that do not go to cervical screening or do not take 
opportunistic Pap-smears, will not be diagnosed and are misclassified as being healthy. This 
would not be a problem if this misclassification is non-differential by vaccination status with 
regards to vaccine effectiveness results as analyzed in the total population. We have 
performed an additional analysis including recently screened women only, i.e. lesions 
detected approximate lesions present, and the results on vaccine effectiveness seen in the 
screened population were comparable to those seen in the total population. These results 
indicated that the misclassification of women with CIN2+ or CIN3+ as healthy is non-
differential by vaccination status. 
5.4 MISCLASSIFICATION OF VACCINATION EXPOSURE  
There has been some underreporting of HPV vaccinations to SVEVAC which might have 
resulted in misclassification of the exposure, i.e. HPV-vaccinated women were considered 
falsely unvaccinated. However, the individuals that could be reimbursed for the HPV vaccine 
could only receive the reimbursement if vaccine doses were dispensed at the pharmacy. 
Vaccine dispensations were subsequently registered in the PDR. Since both PDR and 
SVEVAC were used, misclassification of exposure was minimized during the opportunistic 
vaccination period. 
5.5 AGE AT VACCINATION INITIATION 
The effect of HPV vaccination on incidence of condyloma has been shown to vary across 
different levels of age at first vaccination (105,106), where the effect of vaccination increases 
with decreasing age at vaccination initiation. Age at vaccination is thereby considered an 
effect modifier. In study I and III, effect modification by age at vaccination initiation was 
corrected for by stratifying on age at first vaccination which was based on individuals’ 
vaccination status (vaccinated or not vaccinated) and if vaccinated, the age of vaccination 
initiation. 
5.6 ATTAINED AGE 
Age at vaccination initiation is not equivalent to attained age. The age an individual starts 
vaccination cannot change over time once vaccination is initiated. In contrast, individuals 
attain age during follow up. The incidence of condyloma (study I) and cervical lesions (study 
III) highly depend on attained age. Attained age is considered a confounder as the rate of 
condyloma (study I) and cervical lesions (study III) change with age. Furthermore, efforts 
made to vaccinate girls and young women were mainly directed towards girls’ ages 13 to 17 
years in the opportunistic vaccination period, and to girls ages 10 to 18 afterwards. The 
likelihood of getting vaccinated therefore depends on age. Attained age was subsequently 
adjusted for by including attained age as an underlying time-scale in the analyses. 
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6 DISCUSSION, IMPLICATIONS, CONCLUSIONS 
Individuals that were HPV-vaccinated in Sweden during the opportunistic vaccination period 
have been vaccinated with either the bHPV or qHPV vaccine. Both vaccines include 
protection against HPV types 16 and 18 that are found in about 70% of the cervical cancer 
cases. This means that vaccinated individuals are still at risk of developing cervical lesions 
which can develop into cervical cancer as a result of non-vaccine types. To optimally benefit 
from cervical cancer prevention programs, vaccinated women will need to continue cervical 
screening. Study II showed that individuals, opportunistically vaccinated, were equally likely, 
if not more likely to attend cervical screening. Since screening attendance in this study was 
based on a cohort of opportunistically vaccinated women, it remains unclear how these 
results translate to cohorts vaccinated via organized HPV vaccination programs. The girls that 
get HPV-vaccinated free-of-cost via organized vaccination programs today might have 
different attitudes towards cervical screening compared to cervical screening behaviors of 
women that actively choose to get vaccinated out-of-pocket. Therefore, to optimize cervical 
cancer prevention efforts, continued monitoring of screening attendance in populations 
vaccinated via organized HPV vaccination programs, and unvaccinated populations, will be 
needed to anticipate changes in attendance that might compromise the effectiveness of the 
cervical screening programs. If 80% of women are vaccinated, the cervical screening 
program will require changes, ex. the cytology test for young women could be replaced by 
primary HPV testing. While study II has showed that there are no indications so far that 
cervical screening rates drop over time in women opportunistically vaccinated, we need to 
ensure that women opportunistically vaccinated keep going to cervical screening. 
Studies I and III assessed the impact of vaccination on HPV-related disease in the population. 
As it will take several years before the impact on cervical cancer can be assessed, condyloma 
and cervical lesions, CIN2+ and CIN3+, were used as outcomes and surrogate markers for 
vaccination impact on cervical cancer incidence. Population level effect of three-dose 
vaccination against condyloma has been shown previously in various countries, including 
Sweden (105–107). Study III estimated the impact of HPV vaccination on incidence of 
cervical lesions. Greatest reductions in risk for cervical lesions were seen if vaccination was 
initiated at a young age, highlighting the importance of early vaccine administration in young 
girls. In addition, cervical lesions diagnosed in younger girls are more often positive for HPV 
types 16 and/or 18 (108–110), and in theory, greater impact of HPV vaccination against 
cervical lesions can be expected in young girls. The results found in study III support these 
findings; the observed vaccine effectiveness against CIN2+ and CIN3+ in study III was high, 
especially in those younger at vaccination with risk reductions of 75% and 84% for CIN2+ 
and CIN3+, respectively. Furthermore, the results found in study III were in line with results 
from population-based studies conducted in countries other than Sweden (111–115). 
Study I was the first study to report on the effect of vaccination with less than three doses of 
the qHPV vaccine on incidence of HPV-related disease in the population. The results showed 
greatest protection against condyloma after vaccination with three doses of the qHPV 
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vaccine, though receipt of two doses of the qHPV vaccine also resulted in considerable 
reduction in risk for condyloma. One more population-based study has now reported on dose 
effectiveness against condyloma and showed similar results: lower incidence of condyloma 
with each additional dose (116). In addition, this study showed that the effect of two-dose 
vaccination on condyloma incidence approached that of three-dose vaccination when two 
doses were received with more time between dose one and two (116). Furthermore, other 
studies have reported on impact of vaccination on cervical lesions per dose level (112,113), 
and found a lower incidence of cervical lesions with each additional dose. However, the 
effect of vaccination on cervical lesions per dose level in the Swedish population, including 
timing between dose one and two, has not been published yet. 
Estimates of vaccine effectiveness can easily be biased. For example, if vaccination coverage 
is high enough, it is expected that unvaccinated individuals will benefit via herd protection. 
Comparing disease incidence in vaccinated individuals with unvaccinated and partially 
vaccinated individuals will, in that case, be biased towards an underestimation of vaccine 
effectiveness. The vaccination coverage remained low during the opportunistic vaccination 
period, and it was not likely that such bias was present in studies I and III. However, with the 
introduction of organized vaccination programs, vaccination coverage has increased and both 
direct and indirect effects of vaccination are anticipated. Future studies on vaccination 
effectiveness should therefore consider such bias when assessing vaccination effectiveness. 
Population level impact of HPV vaccination on prevalence of HPV vaccine types has been 
reported in several countries (44,45,117,118). In Sweden, reduction of HPV types 6, 11, and 
16 have been observed with decreases in prevalence of 40%, 41.6%, and 45.6%, respectively, 
in girls ages 14 to 22 (117). With an incubation time of typically 1 to 6 months (57,58), 
condyloma is the first HPV-related disease outcome that can be used to assess the effect of 
vaccination and its effect on disease reduction in the population. Direct effects of vaccination 
are expected in birth cohorts with higher HPV vaccination coverage, whereas indirect effects 
of vaccination, through reduced transmission rates of the virus from cohorts with higher 
vaccination coverage, are expected in men and birth cohorts of women with low vaccination 
coverage. The expected effects of vaccination in the population depend on various factors 
such as the implementation of HPV vaccination programs, type of program, i.e. opportunistic 
or organized, and the achieved vaccination coverage. It has been shown that vaccination 
coverage is related to reductions of condyloma cases and HPV type 16 and 18 infections (45). 
These parameters vary across countries and results cannot directly be extrapolated across 
other countries. In study IV, an ecological study design was used to monitor trends in burden 
of condyloma over time shortly after qHPV vaccine introduction. Condyloma cases were not 
linked to HPV vaccination status, but instead, summary estimates were used to provide 
information on population trends. Reductions in incidence of condyloma were seen in both 
men and women. The greatest reductions were seen in girls at those ages where vaccination 
coverage was highest. Reductions were also seen in the corresponding age-groups of boys, 
but the point in time where incidence started to decrease occurred slightly later, which could 
be interpreted as herd protection.  
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CONCLUSIONS 
Women that have been HPV vaccinated through opportunistic HPV vaccination were equally 
likely, if not more likely to attend organized cervical screening following an invitation letter 
to cervical screening. Maximum reductions in risk for CIN2+ and CIN3+ were seen 
following three-dose vaccination in girls and young women that initiated vaccination up until 
age 29. Greater reduction in risk for CIN2+ and CIN3+ were seen in those younger at 
vaccination initiation; maximum reductions of 75% and 84% in risk for CIN2+ and CIN3+ 
were seen in those who initiated vaccination prior to age 17. 
Maximum reduction in risk for condyloma was observed after vaccination with 3 doses of the 
qHPV vaccine. Vaccination with two doses of the qHPV vaccine was also associated with a 
considerable reduction in risk for condyloma. Though risk for condyloma was reduced for all 
girls and young women under study, greater risk reductions were seen in those younger at 
vaccination initiation with a maximum reduction in risk for condyloma of 82% seen after 
three-dose vaccination in those under age 17 at vaccination initiation. 
Declines in condyloma incidence in girls below age 20 were seen following the introduction 
of qHPV vaccination in Sweden and confirm anticipated effects. The observed decline among 
men and in women age 20 and above indicates possible herd protection.  
Future monitoring of the disease burden over time, as well as observational studies 
comparing vaccinated and unvaccinated individuals, are necessary to evaluate whether the 
organized school-based vaccination program has the anticipated effect in the population. 
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7 FUTURE DIRECTIONS 
The HPV vaccines’ protective properties against vaccine HPV type related and non-vaccine 
HPV type related infections, condyloma, precursor lesions of cervical cancer, and other 
precursor lesions of HPV-related cancers have been shown in both clinical trial and 
population-based settings. How these results translate in terms of protection against cervical 
cancer has yet to be determined. However, based on results of the effect of vaccination on 
risk for cervical lesions, which is an appropriate intermediate disease outcome between an 
HPV infection and cervical cancer, a protective effect of HPV vaccination on invasive 
cervical cancer can be anticipated (34). 
The bHPV and qHPV vaccines have been on the market for almost a decade. Population-
based studies have extrapolated findings from clinical trials. However, some questions remain 
unanswered. Though long-term protection is assumed, the duration of protection after HPV 
vaccination against HPV infection and HPV-related disease remains unclear for both the 
initially recommended three-dose schedule and the new two-dose recommendations. 
Furthermore, the protective properties of HPV vaccination against infections and lesions 
caused by non-vaccine HPV types have been shown. Kemp et al. has shown that, following 
vaccination, neutralizing antibodies of HPV types 31 and 45 were about 100 times lower than 
levels observed for HPV types 16 and 18 (119). It remains unclear whether there are 
differences in the duration of protection between vaccine and non-vaccine HPV types 
(42,43,119). This information will be of particular value for policy makers and serve as input 
for cost-effectiveness models. 
Now that organized HPV vaccination programs are in place in Sweden and vaccination 
coverage has reached higher levels of 60% in catchup programs and 80% in organized 
school-based programs (81), the incidence of condyloma and other HPV-related diseases are 
expected to go down. It will be important to monitor and maintain subsequent vaccination 
coverage to anticipate changes in vaccine uptake. But also close monitoring of circulating 
HPV types will be required to investigate the cross-reactive properties of the HPV vaccines 
and determine possible HPV type replacement (82). Disease surveillance using an ecological 
design does not provide information on type replacement, or waning immunity resulting in 
increases in disease incidence. Typing of HPV-related lesions in a subset of the population 
and vaccination effectiveness studies can provide information on these issues. 
Soon there will be a mixture of opportunistically vaccinated cohorts from when there were no 
organized programs in place or as part of the catchup vaccination program, and birth cohorts 
that have been vaccinated with either two or three doses of the qHPV vaccine within the 
school-based vaccination program. In the future, there will also be birth cohorts that will be 
vaccinated with next-generation vaccines. Now that the 9vHPV vaccine has been 
recommended by the EMA for commercial use, countries have the opportunity to include the 
9vHPV vaccine in the national HPV vaccination programs thereby maximizing prevention 
efforts of HPV related disease. This needs to be done in a systematic manner.  However, 
these birth cohorts all remain at risk for cervical cancer and will need to go to screening, but 
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with different prerequisites. The cervical screening guidelines require adaptation to optimize 
cervical cancer prevention efforts while achieving cost-effectiveness. 
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